News Astellas' Iveric takeover rewarded with FDA nod for GA drug The FDA has approved a new drug for sight-robbing disease geographic atrophy from Astellas, just a few weeks after the company
News Astellas cuts $5.9bn deal to buy Iveric Bio Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,
R&D Sponsored From Alzheimer’s disease research to the real-world setting:... In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
